Page 486 - Read Online

Gajjar et al. ERCC1 in colorectal cancer

Patient consent 12. Zaanan A, Dalban C, Emile JF, Blons H, Fléjou JF, Goumard C,
Patient consent was acquired from all patients prior to Istanbullu M, Calmel C, Alhazmi K, Validire P, Louvet C. ERCC1,
sample collection. XRCC1 and GSTP1 single nucleotide polymorphisms and survival
of patients with colon cancer receiving oxaliplatin-based adjuvant
chemotherapy. J Cancer 2014;5:425-32.
Ethics approval 13. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz
The study has been approved by Institutional Scientific HJ. A multivariate analysis of genomic polymorphisms: prediction of
and Ethical Committees. clinical outcome to 5-FU/oxaliplatin combination chemotherapy in
refractory colorectal cancer. Br J Cancer 2004;91:344-54.
REFERENCES 14. Wang AT, Sengerová B, Cattell E, Inagawa T, Hartley JM, Kiakos
K, Burgess-Brown NA, Swift LP, Enzlin JH, Schofield CJ, Gileadi
O, Hartley JA, McHugh PJ. Human SNM1A and XPF-ERCC1
1. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach
L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J. Fluorinated collaborate to initiate DNA interstrand cross-link repair. Genes Dev
pyrimidines, a new class of tumour-inhibitory compounds. Nature 2011;25:1859-70.
1957;179:663-6. 15. Li Y, Liu Z, Liu H, Wang LE, Tan D, Ajani JA, Wei QY. ERCC1 and
2. Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of ERCC2 variants predict survival in gastric cancer patients. PLoS One
resistance and reversal strategies. Molecules 2008;13:1551-69. 2013;8:e71994.
3. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy 16. Huang MY, Wang JY, Huang ML, Chang HJ, Lin SR. Polymorphisms
J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, in XPD and ERCC1 associated with colorectal cancer outcome. Int J
Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Mol Sci 2013;14:4121-34.
Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin 17. Kim CY, Seo SH, An MS, Kim KH, Bae KB, Hwang JW, Kim JH, Kim
as first-line treatment in advanced colorectal cancer. J Clin Oncol BM, Kang MS, Oh MK, Hong KH. ERCC1 as a predictive marker
2000;18:2938-47. for FOLFOX chemotherapy in an adjuvant setting. Ann Coloproctol
4. Chang PM, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang 2015;31:92-7.
JK, Wang HS, Wang WS. ERCC1codon 118 C→T polymorphism 18. Liang R, Lin Y, Liu ZH, Liao XL, Yuan CL, Liao SN, Li YQ.
associated with ERCC1 expression and outcome of FOLFOX-4 Correlation between ERCC1 expression and concurrent chemotherapy
treatment in Asian patients with metastatic colorectal carcinoma. and radiotherapy in patients with locally advanced nasopharyngeal
Cancer Sci 2009;100:278-83. cancer. Genet Mol Res 2015;14:5804-11.
5. Dabholkar M, Bradshaw L, Parker RJ, Gill I, Bostick-Bruton F, 19. Yu JJ, Thornton K, Guo Y, Kotz H, Reed E. An ERCC1 splicing
Muggia FM, Reed E. Cisplatin-DNA damage and repair in peripheral variant involving the 5′UTR of the mRNA may have a transcriptional
blood leukocytes in vivo and in vitro. Environ Health Perspect modulatory function. Oncogene 2001;20:7694-8.
1992;98:53-9. 20. Qi YJ, Cui S, Yang YZ, Han JQ, Cai BJ, Sheng CF, Ma Y, Wuren
6. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the T, Ge RL. Excision repair cross-complementation group 1 codon
roles of nucleotide excision repair and recombination in the repair 118 polymorphism, micro ribonucleic acid and protein expression,
of DNA interstrand cross-links in mammalian cells. Mol Cell Biol clinical outcome of the advanced gastric cancer response to first-line
2000;20:7980-90. FOLFOX-4 in Qinghai-Tibetan plateau population. J Cancer Res Ther
7. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: 2013;9:410-5.
mechanism of action and antineoplastic activity. Semin Oncol 21. Takenaka T, Yano T, Kiyohara C, Miura N, Kouso H, Ohba T, Kometani
1998;25:4-12. T, Shoji F, Yoshino I, Maehara Y. Effects of excision repair cross-
8. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementation group 1 (ERCC1) single nucleotide polymorphisms
complementing-group 1: gene expression and platinum resistance. Int on the prognosis of non-small cell lung cancer patients. Lung Cancer
J Mol Med 2004;14:959-70. 2010;67:101-7.
9. Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, 22. Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC,
Yun J, Sones E, Mallik N, Lenz HJ. ERCC1 gene polymorphism as a Ducreux M, Sarasin A, Praz F. ERCC1 codon 118 polymorphism is a
predictor for clinical outcome in advanced colorectal cancer patients predictive factor for the tumor response to oxaliplatin/5-fluorouracil
treated with platinum-based chemotherapy. Clin Adv Hematol Oncol combination chemotherapy in patients with advanced colorectal
2003;1:162-6. cancer. Clin Cancer Res 2005;11:6212-7.
10. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ. 23. Martinez-Balibrea E, Abad A, Aranda E, Sastre J, Manzano JL, Díaz-
Prognostic value of expression of ERCC1, thymidylate synthase, Rubio E, Gómez-España A, Aparicio J, García T, Maestu I, Martínez-
and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin Cardús A, Ginés A, Guino E; Spanish Group for the Treatment of
chemotherapy in advanced gastric cancer. Ann Oncol 2007;18:504-9. Digestive Tumours. Pharmacogenetic approach for capecitabine
11. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision or 5-fluorouracil selection to be combined with oxaliplatin as first-
repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. line chemotherapy in advanced colorectal cancer. Eur J Cancer
Biochem Pharmacol 2000;60:1305-13. 2008;44:1229-37.

476 Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ December 29, 2016